Key result
In patients with chronic heart failure, elevated urinary NAG (> median) independently predicted the progression of chronic kidney disease over a 5-year follow-up (OR 3.25, P=0.013).
Why the study?
Do urinary biomarkers NAG, KIM-1, and NGAL predict long-term progression of chronic kidney disease in patients with chronic heart failure?
Population
149 patients with chronic heart failure (follow-up available for 138)
Design
Cohort
Follow-up
5 years
Authors
Loading...
Novel urinary biomarkers may refine CKD progression risk in CHF; leaves open incremental value beyond standard predictors.
Cohort (n=149)
Do urinary biomarkers NAG, KIM-1, and NGAL predict long-term progression of chronic kidney disease in patients with chronic heart failure?
Odds Ratio: 3.25
p-value: p=0.013
Urinary tubular biomarkers NAG and KIM-1 are independent predictors of long-term CKD progression in patients with chronic heart failure.
Jungbauer et al. (2015) conducted a cohort in Chronic heart failure (n=149). N-acteyl-ß-D-glucosaminidase (NAG) and kidney injury molecule-1 (KIM-1) vs. Lower biomarker levels (e.g., NAG ≤ median) was evaluated on Progression of CKD (decline in eGFR category accompanied by a ≥25% drop in eGFR from baseline) (OR 3.25, p=0.013). In patients with chronic heart failure, elevated urinary NAG (> median) independently predicted the progression of chronic kidney disease over a 5-year follow-up (OR 3.25, P=0.013).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: